Ga-nns309

Other Medications

Description

Ga-nns309 is an investigational medication currently being studied in clinical trials. It is used in conjunction with another investigational drug called Lu-dfc413. In the trials, patients first undergo a scan using Ga-nns309, a type of PET scan, to see if they are eligible for treatment with Lu-dfc413. This scan helps doctors determine if the treatment might be effective for that specific patient. The trials are evaluating the safety and effectiveness of this approach in patients with certain types of solid tumors, including colorectal cancer. The trials are in the early phase (Phase 1), meaning they are primarily focused on determining the right dose and assessing safety.

Mechanism of Action

Ga-nns309 is a radioactive tracer used for imaging (PET scan). It binds to specific targets on cancer cells, allowing doctors to visualize the tumor and potentially assess its characteristics. This imaging helps determine which patients might benefit from treatment with Lu-dfc413. The specific molecular target of Ga-nns309 is being characterized in clinical trials.

Side Effects

As Ga-nns309 is used primarily for imaging in early-phase trials Specific side effect data is limited. Side effects related to the PET scan itself (like radiation exposure) are generally minimal. The side effects associated with the subsequent treatment (Lu-dfc413) would be evaluated separately. More comprehensive safety and side effect information is expected as the clinical trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07261631 Phase 1
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Canada, Denmark, France, Germany, Israel, Singapore
NCT07630961 Phase 1
Not yet recruiting
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors